Last updated: April 23, 2026
What suppliers produce guaifenesin (API)?
Common global suppliers of guaifenesin (active pharmaceutical ingredient, API) and guaifenesin-related intermediates include:
| Company |
Typical role |
Notes |
| Mylan (Viatris) |
API supplier |
Large-scale branded and generic manufacturing footprint in cough/cold categories |
| Hetero Labs |
API supplier |
Broad respiratory and OTC API portfolio |
| Teva API |
API supplier |
Scale in OTC and generic APIs |
| Cipla |
API supplier |
API supply for respiratory symptom products |
| Zhejiang NHU |
API supplier |
Manufactures guaifenesin for downstream formulations |
| Zhejiang Hisun |
API supplier |
Respiratory and OTC API presence in China |
| Zhejiang Wansheng |
API supplier |
Regional API producer serving cough/cold markets |
| Aarti Drugs |
API supplier |
Intermediate and API supply chain for expectorants |
What suppliers produce pseudoephedrine hydrochloride (API)?
Pseudoephedrine hydrochloride API sits in a high-control regulatory category in many jurisdictions, so supply is concentrated among established API manufacturers with compliance systems and licensing.
| Company |
Typical role |
Notes |
| Hisun Pharma (Hisun) |
API supplier |
China-based API manufacturing with global customer base |
| Zhejiang NHU |
API supplier |
Long-running supplier of OTC cold/cough APIs |
| Mylan (Viatris) |
API supplier |
Generic manufacturing footprint for controlled-substance precursor-linked workflows |
| Teva API |
API supplier |
Supply into global generic OTC pipelines |
| Aarti Drugs |
API supplier |
Backward integration and intermediate capability for regulated APIs |
| Wuhan Yuanchang |
API supplier |
Pseudoephedrine-related chemical supply capacity in China |
| Global suppliers via toll manufacture |
API supplier |
Common in regulated APIs where local compliance and licensing matter |
How do supplier choices differ between guaifenesin and pseudoephedrine HCl?
| Dimension |
Guaifenesin |
Pseudoephedrine HCl |
| Regulatory intensity |
Lower than pseudoephedrine |
Higher due to diversion controls tied to precursor/regulated pathways |
| Supply concentration |
Broader base of API suppliers |
Narrower base among licensed, audit-ready manufacturers |
| Customer qualification |
Standard cGMP qualification |
Stricter compliance and documentation expectations |
| Logistics and documentation |
Standard API QA pack |
Enhanced controls on chain-of-custody, end-use declarations, and shipment records |
What documentation and qualification artifacts do buyers typically require?
For both APIs, procurement teams normally lock suppliers against a qualification and compliance package that includes:
- GMP status: manufacturer certificate(s) of analysis and GMP compliance statements for API manufacture and packaging
- CoA and release specs: assay, impurities, residual solvents (if applicable), water content (if applicable), particle size (if relevant)
- Regulatory file readiness: DMF/ASMF or equivalent dossier support when customers require registration readiness
- Analytical validation: stability-indicating method support for shelf life programs
- Quality systems: deviation and CAPA history, change control policy, and audit reporting
For pseudoephedrine hydrochloride, the documentation stack is typically heavier around diversion-control requirements.
How should you structure a sourcing shortlist for each API?
For guaifenesin API
- Build a shortlist of 4 to 8 suppliers based on: manufacturing scale, impurity profile control, and delivery performance into OTC/generic customers.
- Screen for customers who already source the same strength/forms (base vs HCl salts, if applicable) and who can share stability and packaging outcomes.
For pseudoephedrine HCl API
- Build a shortlist of 2 to 5 suppliers based on: regulatory licensing track record, audit outcomes, and chain-of-custody controls.
- Prioritize suppliers that can support: end-use declarations and compliant shipping documentation for the destination market.
What are typical sourcing risk hotspots by API?
| Risk hotspot |
Guaifenesin |
Pseudoephedrine HCl |
| Supply continuity |
Moderate competition; risk tied to plant downtime |
High due to diversion-control constraints and licensing/inspection cycles |
| Regulatory scrutiny |
Lower |
Higher; documentation and distribution controls can slow onboarding |
| Quality drift |
Route/impurity changes |
Impurity and residuals control plus documentation completeness |
| Forecast accuracy |
Needed to avoid stock-outs |
Critical because supply often tightens during compliance cycles |
Key Takeaways
- Guaifenesin has a broader set of established API suppliers across Asia and global generic supply networks.
- Pseudoephedrine hydrochloride is more supply-concentrated, with qualification driven by regulatory controls and chain-of-custody requirements.
- Buyers should treat sourcing as two tracks: standard GMP and analytical readiness for guaifenesin, versus GMP plus diversion-control compliance for pseudoephedrine HCl.
- The most actionable supplier shortlists rely on audit-ready documentation, supply continuity history, and proven performance for the exact API form required.
FAQs
1) Are guaifenesin and pseudoephedrine hydrochloride normally sourced from the same manufacturers?
Often not. Guaifenesin can come from a wider set of OTC API producers, while pseudoephedrine HCl supply is more restricted to manufacturers with diversion-control compliance maturity.
2) What’s the biggest reason pseudoephedrine HCl sourcing takes longer than guaifenesin?
Regulatory controls tied to diversion risk drive heavier qualification, documentation, and chain-of-custody requirements.
3) Do buyers always require a DMF/ASMF for these APIs?
For many markets and large customers, dossier support via DMF/ASMF (or equivalent) is a standard qualification criterion.
4) What quality attributes matter most for API acceptance?
Assay, impurity profile, residual solvents (if applicable), water content (if applicable), and stability-indicating method capability.
5) Can supply constraints swing within a year?
Yes. Guaifenesin can face manufacturing downtime risks; pseudoephedrine HCl can face additional tightening during licensing, inspections, and compliance-driven enforcement periods.
References
[1] FDA. Drug Databases (Drugs@FDA and related information). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency (EMA). European public assessment reports and regulatory product information. https://www.ema.europa.eu/en/medicines
[3] ICH. Q-series guidelines for pharmaceutical development and quality. International Council for Harmonisation. https://www.ich.org/page/quality-guidelines
[4] DEA. Controlled substances and regulatory requirements (U.S.). U.S. Drug Enforcement Administration. https://www.dea.gov/
